15 results
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
the European Society of Microbiology and Infectious Disease (or ESCMID) scientific congress held in April 2024 where Dr. Kevin Garey, Professor and Chair … as data become available, at various prominent scientific conferences including:
The Houston Cdiff and Microbiome conference;
The Anaerobe Society
FWP
ACXP
Acurx Pharmaceuticals Inc
2 Apr 24
Free writing prospectus
7:31am
by the Infectious Diseases Society of IDSA and SHEA 2 Johnson,et al: Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium … Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). April 2018
Advancing a New Class of Antibiotics to Phase 3
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
for Gram-positive Bacterial Infections: Preparing for the Next Pandemic".
The IDSA (Infectious Diseases Society of America) convened its annual meeting … Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals Inc
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society
8-K
EX-99.1
ke2fxof475 npmh7c
2 Oct 23
Other Events
4:41pm
8-K
EX-99.1
3k1rihhe91tsnp
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am
8-K
EX-99.1
dnmgrw9
14 Nov 22
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
7:11am
8-K
EX-99.1
ikrfwgfr9vveq5st34j
15 Aug 22
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides
4:19pm
10-K
wce1b
16 Mar 22
Annual report
4:05pm
424B4
pqy 76ikzi8v
28 Jun 21
Prospectus supplement with pricing info
6:02am
S-1/A
y7z5dm9edar
11 Jun 21
IPO registration (amended)
6:02am
S-1
f44lb6txv8ca0t57m
27 May 21
IPO registration
12:00am
DRS/A
l60fod21f
10 May 21
Draft registration statement (amended)
12:00am
DRS
b8fkytwy1a9jf2h53sz
5 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next